Page 12 - Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Prevention of osteoporosis

• All men with mCNPC/mCSPC treated with ADT should be assessed for

fracture risk

• All men treated with ADT require vitamin D supplementation (800–1200

IU daily) and calcium supplementation (800–1000 mg total intake daily)

• Those at high risk of fractures should be treated (zoledronic acid 5 mg
once a year, alendronate 70 mg weekly, denosumab 60 mg every six

months)

ADT: androgen-deprivation therapy; mCNPC: metastatic castration-naive prostate cancer; mCSPC: metastatic
castration-sensitive prostate cancer